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Nanobelt carriers have demonstrated some advantages such as good biocompatibility, biodegradability, and
strain-accommodating properties. We prepared an optimized nanobelt carrier formulation for drug (etoposide)
as an oral delivery system and estimated the potential of calcium carbonate (CaCO3) nanobelts. The nanobelts
were prepared by the method of binary solvent approach and were characterized by transmission electron microscope
(TEM), scanning electron microscopy (SEM), and ultraviolet–visible (UV–vis) spectra. MTT (3-(4,5-dimethyl-2-thiazolyl)-2,
5-diphenyl-2H-tetrazolium bromide) assay test exhibited that etoposide-loaded calcium carbonate nanobelts (ECCNBs)
showed a higher cell kill ratio against SGC-7901 cells compared with free drug. The apoptosis test and cell cycle test
analysis revealed that etoposide entrapped in calcium carbonate nanobelts (CCNBs) could enhance the delivery
efficiencies of drug and improved inhibition effect. The present findings demonstrated that ECCNBs might
induce cell cycle arrest at G2/M phase and cell apoptosis in a p53-related manner. It can be foreseen that
CCNBs are a promising drug carrier to store the anti-cancer drug for cancer therapy and drug delivery.
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Nowadays, cancer has become one of the main causes of
death worldwide [1]. As cancer proliferates, many clin-
ical cancer therapies have been developed, such as sur-
gery, radiotherapy, and chemotherapy [2]. There existed
some problems in chemotherapeutic drugs, such as the
development of drug resistance, low bioavailability, and
undesirable severe side effects [3, 4]. For example, eto-
poside (code designation VP-16-213, abbreviated VP16),
a topoisomerase II inhibitor, is widely used as a chemo-
therapeutic agent currently in clinical trials for small cell
lung cancer, lymphomas, and testicular cancers [5–8].
The formation of a complex of DNA-drug-enzyme can
cause DNA double-stranded breaks to interfere with VP-
16 topoisomerase II activity [9]. As we know, the entire
VP16-induced apoptosis signaling pathways are not
clear. But the DNA damage induced by VP16 has been* Correspondence: wsl@tongji.edu.cn; zhudz@tongji.edu.cn
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in any medium, provided the original work is pshown that it can activate the activity of p53 [10, 11].
Therefore, it is significant to explore its signal path.
Despite its extensive researches and developments, its
clinical application was limited because of its side effect
for normal tissue, extremely poor aqueous solubility, and
it damages intestinal and hepatic metabolism [12, 13].
Therefore, some lab successfully solved the problem by
developing the smart and innovative drug delivery sys-
tems in biomedical applications (such as superparamag-
netic multistage delivery system [14], supramolecular
microcapsules controlled release delivery system [15]).
Calcium carbonate (CaCO3) and its products have a
wide application. CaCO3 is a typical biomaterial, which
can be used in many products, such as cosmetics and
toothpastes, and in the paper industry. Compared with
other inorganic materials, calcium carbonate is exceed-
ingly suitable because of its ideal properties of bio-
degradability and biocompatibility [16]. Furthermore, it
has also been used as a smart carrier to deliver genes,
enzymes, and drugs [17–22]. The property of pH sensi-
tivity enables CaCO3 to be used for controlled degrad-
ability both in vitro and in vivo test [23].
Herein, we developed the novel CaCO3 nanobelts as
the carrier for the drug delivery and cancer therapy.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and easily performed, which is based on the binary solv-
ent approach used by Peng [24]. We evaluate the drug-
loading efficiency of etoposide-loaded calcium carbonate
nanobelts (ECCNBs) and the drug release behaviors at dif-
ferent pH value. Otherwise, cellular experiments of MTT
(3-(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium
bromide) assay and cell cycle analysis were tested to evalu-
ate the anti-cancer effect and biocompatibility of ECCNBs.
Besides, the confocal laser scanning microscopy (CLSM)
images were utilized to investigate the uptake ability
of calcium carbonate nanobelts (CCNBs) by cancer
cells. We also discussed the cellular uptake mechan-
ism of the CCNBs. These results demonstrated that
the nanobelts could be potentially applied as effective
drug carrier for cancer treatment.
Methods
Materials
Etoposide (≥98 %) was a kind gift from the University of
Science and Technology of China. Ethanol (analytical re-
agent (AR)), citric acid (AR), CaCl2 (AR), Na2CO3 (AR),
and HCl (36–38 %) were purchased from Sinopharm
Chemical Regent Co., Ltd. (Shanghai, China). Dimethyl
sulfoxide (DMSO) and MTT formazan were purchased
from Sigma Chemical Co. (St Louis, MO, USA). Dulbec-
co’s Modified Eagle Medium (DMEM), Roswell Park
Memorial Institute (RPMI)-1640, fetal calf serum (FCS),
streptomycin, trypsinase, and penicillin G were obtained
from GIBCOBRL (Grand Island, New York, NY, USA).
Deionized water was decarbonated when it was used in
the experiments.
Cell Lines and Culture Conditions
Human gastric carcinoma cells (SGC-7901) obtained
from the Chinese Academy of Sciences Cells Bank,
Shanghai, China, were routinely cultured in RPMI-1640
cell medium supplemented with 10 % FBS, 100 U/mL
penicillin, and 100 mg/mL streptomycin, at 37 °C in 5 %
CO2 and 95 % air atmosphere with >95 % humidity. All
experiments were performed on cells in the logarithmic
phase of growth.
Synthesis of ECCNBs
ECCNBs were synthesized by mixing CaCl2, citric acid,
and Na2CO3 aqueous solution, which also include eto-
poside and ethanol. Solution I: 10 mL CaCl2 (0.1 M) and
0.2 g etoposide were dissolved in 40 mL of the water
and 20 mL of ethanol mixtures. Solution II: 10 mL of
Na2CO3 (0.1 M) and 0.2 g citric acid were dissolved in
40 mL of the water and 20 mL of ethanol mixtures. So-
lution II was added dropwise to the Solution I with a
vigorously stirred speed of 1000 rpm. After 72 h, we can
obtain milky white precipitation. The precipitation waswashed thrice with 40 mL of the water and 20 mL of
ethanol mixtures first and then should be dried by vac-
uum freeze drier. The synthetic parameters of the blank
carrier (CCNBs) were similar to the ECCNBs sample.
The difference between CCNBs and ECCNBs is without
the addition of VP16.
Physical Characterization of Nanobelts
The obtained products were characterized by scanning
electron microscopy (SEM, Hitachi S4800, Chiyoda-Ku,
Japan) and transmission electron microscope (TEM). The
morphological and spatial studies were carried out with
field emission scanning electron microscopy (FESEM, JEOL
1230, Tokyo, Japan) at an accelerating voltage of 1–5 kV.
The surface morphology of CCNBs was obtained by trans-
mission electron microscope.
Fourier Transform Infrared (FTIR) Spectral and Ultraviolet–
visible (UV–vis) Spectral Study
FTIR measurement was recorded on a Bruker Vector 22
spectrophotometer (Madison, WI, USA) using the standard
KBr disk method in the range of 4000 to 500 cm−1. For
FTIR spectral study, CCNBs, free VP16, and ECCNBs were
ground into power with KBr to get the pellets by applying a
pressure of 300 kg/cm2. We measured the absorbance spec-
tra of native etoposide (dispersed in ethanol), ECCNBs (dis-
persed in ethanol), and void CCNBs (dispersed in ethanol)
through a Cary 50 UV-visible absorbance spectrophotom-
eter (Varian, Victoria, Australia).
Dispersity Study in RPMI-1640 Medium
Five milligrams etoposide was resuspended in 10 mL
RPMI-1640 medium, which was supplemented with 1 %
penicillin-streptomycin and 10 % fetal bovine serum so-
lution in a glass bottle. The same quantity of etoposide
was applied to ECCNBs for the dispersity study, based
on the drug encapsulation efficiency.
In Vitro Release Test
Ten milligrams of ECCNB sample was placed in a 15-mL
tube. At the same time, 200 μL of 6 M HCl solution was
added into it. Then the tube was filled with phosphate buf-
fer solution (pH = 7.4) until it reached 10 mL. The concen-
tration of VP16 can be monitored at 285 nm through a
UV–vis spectrophotometer, when the ECCNBs sample was
totally dissolved. The drug-loading capacity is work out as
follows:
drug‐loading capacity ¼ weight of etoposide in ECCNBs
weight of ECCNBs
100%
The release test was researched in a system of 200 mL
PBS at pH 4.5 and 7.4, respectively. Twenty-five
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10 mL PBS. The release system was conducted in a bath
reciprocal shaker with 100 rpm at 37 °C. Two milliliters
liquid was extracted at desired time intervals. Another 2
mL of fresh PBS was added to the release system. The
accumulated amount of etoposide released was mea-
sured at 285 nm by UV absorption.Cytotoxicity Assay
The cytotoxicity of CCNBs against the human embry-
onic kidney (HEK) 293T cells was tested by the MTT
assay method. The 293T cells (1 × 104 cells/well) were
seeded on a 96-well polystyrene plate. One hundred
microliters of DMEM (high glucose) medium supple-
mented with 1 % penicillin-streptomycin and 10 % fetal
bovine serum solution was added to each well. After 24
h incubation, CCNBs were added to the wells with a
concentration of 5, 10, 20, and 40 μg/mL in sequence.
The 293T cells were incubated for another 24 or 48 h,
respectively. The control experiment was added with
pure culture medium without any treatment. Before me-
diums were removed, the 293T cells should be incubated
with 20 μL of 5 mg/mL MTT for 4 h under light-
blocking condition. Then 150 μL of DMSO was added
into each well. The absorbance of 490 nm can be mea-
sured by ELX 800 UV reader. Cell viability can be work
out by means of the following formula:
Cell viability %ð Þ ¼ OD490 testð Þ‐OD490 blankð Þ
OD490 controlð Þ‐OD490 blankð Þ
 100%
Inhibition Against SGC-7901 Cells
The anti-tumor effect of CCNBs, ECCNBs, and VP16
against SGC-7901 cells was conducted by MTT test.
SGC-7901 cells (8 × 104 cells/well) were seeded on a 96-
well polystyrene plate. One hundred microliters of
RPMI-1640 medium supplemented with 10 % fetal bo-
vine serum and 1 % penicillin-streptomycin solution was
added to each well. After 24 h incubation, ECCNBs were
added to the wells with a concentration of 5, 10, 20, and
40 μg/mL in sequence. The SGC-7901 cells were incu-
bated for another 24 or 48 h, respectively. The control
experiment was added with pure culture medium with-
out any treatment. Before mediums were removed, the
SGC-7901 cells should incubate with 20 μL of 5 mg/mL
MTT for 4 h under light-blocking condition. Then 150
μL of DMSO was added into each well. The absorbance
of 490 nm can be measured by ELX 800 UV reader. The
inhibition can be work out by means of the following




Fluorescence-Activated Cell Sorter Analysis
Apoptosis assay was conducted with SGC-7901 cells by
an Annexin V-Propidium Iodide (PI) detection kit
(KeyGEN Biotech). SGC-7901 cells were suspended in
RPMI-1640. Then, the cells were incubated for 24 h at
37 °C. Cells were pretreated with ECCNBs at the con-
centration of 30 μg/mL for another 24 h. According to
the drug efficiency, the same quantity of etoposide was
applied to the apoptosis analysis with another incubation
of 24 h. At the prescribed time, the cells were harvested
by trypsinization and washed with ice-cold PBS for 5
min. Then the binding buffer (140 mM NaCl, 10 mM
HEPES, 2.5 mM CaCl2, pH 7.4) should be filled with PI
and Annexin V directly. It should be incubated in the
dark for another 15 min at 37 °C. Then the cells were
monitored on a spectrophotometer of Beckton-Dickinson
(Mountain View, CA, USA) for fluorescence-activated cell
sorting (FACS) analysis.
Confocal Laser Scanning Microscopy
Confocal laser scanning microscope (Leica, Wetzlar,
Germany) equipped with an oil immersion objective
(×60, Zeiss, Oberkochen, Germany) was used to ob-
tained CLSM images of cellular internalization of
VP16 and ECCNBs. Fluorescein isothiocyanate (FITC;
1.5 mg) and 7.67 mg ECCNBs dispersed in 10 mL PBS
at 4 °C overnight avoid light. FITC can incorporate
into ECCNBs by covalent attachment. The resultant
suspension was centrifuged at 8000 rpm to remove the
supernatant. Briefly, SGC-7901 cells with a density of
1.5 × 105 cells per well were seeded in a 24-well plate
at a seeding in 2 mL of growth medium. The cells
should have an incubation time of 24 h at 37 °C. The
attached cells should be treated with an equivalent
dose of native etoposide of ECCNBs. After the pre-
scribed time (1, 2, and 4 h), the cells were washed
thrice (PBS, pH 7.4), collected by trypsinization, and
centrifuged for 5 min at 1000 rpm. Fluorescence im-
ages were acquired at an excitation wavelength of 405
and 488 nm.
Qualitative Cellular Uptake Study via Confocal Microscopy
and Flow Cytometry
For qualitative cellular uptake tests, confocal microscopy
and flow cytometry were both used. SGC-7901 cells (a
seeding density of 1.5 × 105 cells/well) were seeded in
Bioptech tissue culture plates (Bioptechs Inc., Butler,
PA), and 2.0 × 105 cells/well on a 6-well polystyrene
plate for confocal studies and flow cytometry studies,
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ment, the attached cells were then treated with a con-
centration (30 μg/mL) of native VP16 and ECCNBs. For
confocal studies, the cells were incubated for 1, 2, and 4
h and then washed thrice with PBS (pH 7.4) to remove
excessive ECCNBs or native etoposide. Fresh DMEM
(high glucose) medium was added to the plates. Then
the cells were viewed by a confocal laser scanning
microscope. For flow cytometry studies, the cells were
incubated for 4 h and then washed thrice with PBS (pH
7.4) to remove excess ECCNBs or native etoposide and
trypsinized. After the collection of the cell, the PBS (pH
7.4) was used to wash it. Consequently, the cells were re-
suspended with 500 μL PBS (pH 7.4) and transferred
into flow cell tubes. FITC fluorescence was analyzed by
FACS Aria II (Beckton and Dickinson, Sanjose, CA),
after excitation using a 488-nm argon laser. Fluorescence
emission above 530 nm from 10,000 cells were collected,
amplified, and scaled to generate single parameter
histogram.
Cell Cycle Analysis by Flow Cytometry
Flow cytometry was used to analyze the cell cycles. To
analyze the cell cycles, we used a slightly different pro-
cedure. After an overnight plating in 6-well per well,
cells were incubated with 30 μg/mL etoposide, CCNBs,
and ECCNBs for 24 h. At time intervals, the coverslips
with adherent SGC-7901 cells were harvested and
washed with ice-cold PBS twice after 24 h of treatment.
Cells were fixed in precooled 70 % ethanol (diluted with
PBS) for 2 h and then washed with ice-cold PBS twice;
after it was suspended with budding buffer, the cells
were treated with RNaseA and stained with propidium
iodide for 30 min at room temperature. Flow cytometer
was used to analyze the stained cells.
Western Blot Analysis
Casepase-7, casepase-8, casepase-9, and Cyt C (mito-
chondrial cytochrome C) antibodies were purchased
from Cell Signaling Technology. The antibody of p53
was purchased from Santa Cruz Biotechnology. Briefly,
the SGC-7901 cells were assessed by the western blot
analysis. Then, the total protein was extracted by chem-
ical methods. Protein content was determined by BCA
protein assay reagent (KeyGen, Nanjing, China). Equal
amount of the proteins (50 μg) of each sample was re-
solved on SDS-PAGE and then electro transferred to
PVDF membrane (Millipore Corp.). Nonspecific binding
was blocked by incubation with 5 % nonfat milk in
Tris-buffered saline containing 0.1 % Tween-20 (TBST)
for 1 h at room temperature. The blots were probed
with respective primary antibodies (antibodies used were
against p53, casepase-7, casepase-8, casepase-9, Cyt C,
and β-actin in 1:1000 dilutions) at room temperatureovernight and washed three times with TBST. The blots
were then incubated with secondary antibody for 30 min
and washed again three times with TBST, and signals
were visualized by chemiluminescent ECL detection
system.
Statistical Analysis
Results were expressed as mean ± standard deviation.
Statistical analyses were performed by using Student’s t
test. Values of P <0.05 were considered statistically
significant.
Results and Discussion
Nanobelts are a class of nanostructure, which are usually
made from semiconducting metal oxides (such as CdSe,
CdO, In2O3 or SnO2, selenides such as ZnO [25–27]).
Nanobelts form ribbon-like structures with thicknesses
of 10–30 nm, widths of 30–300 nm, and lengths in the
millimeter range. They are structurally uniform single
crystals with smooth surfaces and clean edges, posses-
sing rectangular cross sections [28, 29]. The morphology
and size of the CCNBs were characterized by the TEM
and SEM photos (Fig. 1a, b). The particle size distribu-
tion of the nanoparticles was found to be relatively
narrow.
The spectra of etoposide (Additional file 1: Figure S1c)
show the following bands: 1056 cm−1 (C–O–C stretch),
1613 cm−1 (C=O stretch of carboxyl methyl), 1770 cm−1
(C=O stretch of ester bond), and 2923 cm−1 (C–H
stretch), with the bands 1486 and 1404 cm−1 (C=C
stretch) [30]. CaCO3 shows characteristic absorption
peak centered at 875 cm−1 benefits its infrared absorp-
tion spectrum [31]. Additional file 1: Figure S1a, CCNBs
display two strong absorption bands at 875 and 1426
cm−1, which are characteristic absorption bands of cal-
cite. In the FTIR spectra, characteristic CO3
2− peak at
1417 cm−1 and C–O stretching at 1084 cm−1 are present.
Compared with etoposide (c) and CCNBs (a), the spectra of
ECCNBs (b) display the visible characteristic bands of
CaCO3 and also show almost all characteristic vibration
absorption bands of etoposide. The result of FTIR spectra
indicates that CaCO3 nanobelts remained unchanged in the
end.
The drug-loading capacity was calculated as 45 ± 3 %.
To confirm the loading capacity and formulation of eto-
poside loaded in CCNBs, the photophysical property of
etoposide was taken into consideration. Free etoposide,
which dissolved in ethanolic solution, demonstrated its
characteristic absorbance peak at 285 nm (Fig. 1d). The
absorption spectrum of ECCNBs also showed an absorp-
tion band centered at 285 nm, which indicated the exist-
ence of etoposide in ECCNBs. The results of UV–vis
spectra further demonstrated that the etoposide was suc-
cessfully packed into the CCNBs.
Fig. 1 TEM (a) and SEM (b) image of CCNBs. c Sedimentation photographs of free etoposide and ECCNBs in RPMI-1640 medium. d UV–vis spectra
for CCNBs, free etoposide, and ECCNBs
Fig. 2 Release profiles of etoposide from ECCNBs under simulated
physiological conditions (pH 7.4 and pH 4.5 at 37 °C)
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in aqueous solution. To confirm whether our formula-
tion can increase etoposide’s dispersity, the same amount
of native etoposide and ECCNBs were suspended in an
equal volume of RPMI-1640 medium. We found that
ECCNBs dissolved in a medium solution gave a well-
dispersed status (Fig. 1c) in a medium solution. There-
fore, the embedding of etoposide into CCNBs enhanced
the dispersion of the drug in a medium solution.
Figure 2 shows the drug release kinetics of VP16 from
ECCNBs. The drug release behavior from ECCNBs was
examined under the two pH values which simulate the
cellular exterior (pH 7.4) and intracellular lysosome (pH
4.5) [32, 33], respectively. During the first 24 h, the
speed of release was fast, which may be attributed to the
physical adsorption of drugs. After that point, a sus-
tained release from ECCNBs could be observed. Com-
pared to the amount release which was approximately
78 % at pH 7.4, the cumulative drug release is up to 98
% at pH 4.5 in 120 h. If oral administration is chosen,
the ECCNBs can ensure a stable delivery of etoposide
during blood circulation. That is to say, on the one hand,
CCNBs could minimize the drug loss in the blood where
the pH value is neutral and selectively release drugs
when they are internalized into the target cells. On the
other hand, most of the biodegradable ECCNBs can de-
compose in the vicinity of the tumor endotheliumthrough the EPR effect. A stable and fast VP16 release
could be triggered in response to the microenvironment
of tumor tissues. In terms of the delivery efficiency,
ECCNBs would be more promising than native VP16.
The data (Fig. 3a) clearly showed that the carrier
(CCNBs) did not show any cytotoxicity (average residual
remained over 90 %) against normal cells (293T cells). It
Fig. 3 Growth inhibition assay results for 293T cell line with CCNBs after 24 and 48 h incubation (a). Growth inhibition assay results for SGC-7901
cell line with CCNBs, free etoposide, and ECCNBs after 24 and 48 h incubation (b, c). Diagrams were plotted as etoposide concentrations of 5, 10,
20, and 40 μg/mL, respectively. All experiments were carried out in triplicate
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the inhibition effect of CCNBs, VP16, and ECCNBs, against
SGC-7901 cell growth. The figure demonstrates that the
suppression of SGC-7901 cell growth was time and concen-
tration dependent. The inhibition rates of the free VP16
and ECCNBs are 45.37 and 77.53 % at 48 h, respectively.
Clearly, it shows that ECCNBs have a higher suppression
efficiency compared to the native VP16. It is likely that the
good dispersivity of ECCNBs leads to a greater cellular
uptake.
The mechanism of cell growth inhibition was studied
by using Annexin V-FITC Apoptosis Detection Kit.
Figure 4(I) illustrates the percentages of early and late
apoptotic cells of the apoptosis assay, which stained cells
with AnnexinV-FITC and PI labeling. Early apoptosis
was characterized by plasma membrane reorganization,
which was characterized by positive staining for Annexin
V-FITC. Later stage apoptosis was characterized by
DNA damage, which was detected by positive staining
for both Annexin V and PI.
We treated with ECCNBs (20 μg/mL) the free etopo-
side against SGC-7901 cells for 24 h prior to FACS ana-
lysis. Moreover, we set cells without any addition as
control. SGC-7901 cells without any additive showed
0.11 % early apoptosis and 0.33 % later apoptosis in
Fig. 4(Ia). The treatment with etoposide led to 13.41 %
early apoptosis and 7.80 % later apoptosis (Fig. 4(Ib)).Observably, the percentage of cells treated with ECCNBs
that reached later apoptosis increased to 9.96 % and
early apoptosis increased to 23.35 % (Fig. 4(Ic)).
It is well known that topoisomerase II of VP16-induced
cleavage of DNA can mediate the formation of chromo-
somal translocation breakpoints, which can lead to and is
responsible for the expression of oncogenic factors [12].
VP16 can cause apoptosis cascade by coupling DNA
damage to p53 phosphorylation through the action of
DNA-dependent protein kinase in gastric cancer cells [34].
Compared with free VP16 and untreated controls, the
percentage of both early apoptosis and later apoptosis in
ECCNBs group is significantly increased. It demonstrates
that ECCNBs were able to induce the apoptosis pro-
cesses among gastric cancer cells and readily caused the
cells to die. The results show that ECCNBs can enhance
the efficiency of anti-tumor effect.
We evaluated the high therapeutic effect of ECCNBs
by the uptake behavior of SGC-7901 cells. As shown in
Fig. 5(I), ECCNBs passed through the cytomembrane
and eventually assembled in the nucleus at 1, 2, and 4 h,
respectively. The results show the time-dependent cellu-
lar uptake. CLSM images show that the CCNB carriers
could aggregate around the nucleus and even directly
intrude into the nucleus. The enhanced intracellular de-
livery effective therapy may result from the pH-sensitive
release.
Fig. 4 I FACS analysis of SGC-7901 cells stained with AnnexinV-FITC and PI. Cells did not treat with any agents as blank control (a), cells apoptosis
induced by etoposide (b), cells treated with the ECCNBs (c). In all panels, LR represents early apoptosis and UR represents late apoptosis. II Analysis
of cell cycle distribution by flow cytometry: SGC-7901 cells set as control group (a); SGC-7901 cells treated with CCNBs (b); SGC-7901 cells treated
with etoposide (c) (30 μg/mL); SGC-7901 cells treated with ECCNBs (d)
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d4)) and ECCNBs (Fig. 5(e2, e3, e4)) uptake was showed
by plotting the fluorescence peak at different incubation
time of 1 h (d2, e2), 2 h (d3, e3), and 4 h (d4, e4). The
number of events with the high intensity of 30 μg/mL
etoposide increased with its uptake into cells about 4 h
of incubation time. As shown in Fig. 5(II), FACS analysis
showed the cells treated with ECCNBs showed better
profound fluorescence intensity. It indicates that CCNBsinternalized have a better efficiency than native etopo-
side. The result of fluorescence intensity of the ECCNBs
is in agreement with the result of CLSM images.
We examined the effect of etoposide and ECCNBs on
SGC-7901 cell cycle by analyzing the DNA content of
cells, which stained with propidium iodide by flow cy-
tometry. After cultured with 30 μg/mL etoposide and
ECCNBs for 24 h, the cell cycles were conducted by flow
cytometry. As demonstrated in Fig. 4(II), the G2/M cell
Fig. 5 I Confocal laser scanning microscopy (CLSM) images of the ECCNBs (a–c) on SGC-7901 cells at the predetermined point of 1, 2, and 4 h,
respectively. In each case, 1, 2, and 3 indicate DAPI, FITC, and Merge, respectively. II SGC-7901 cells were treated with 30 μg/mL etoposide in two
forms of ECCNBs (e2–e4) and void etoposide (d2–d4). As the plots show, the number of events (y-axis) with high fluorescence intensity (x-axis)
increases by 4 h incubation with ECCNBs but without any evident change for void etoposide. Negative control (d1, e1) includes non-treated cells
to set their auto-fluorescence as “0” value
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and ECCNBs treatment in SGC-7901 cells. Based on
these results, we believe that etoposide might induce G2/
M arrest and exert through its toxic effects on G2 phase
cells and inhibit G2/M transition of SGC-7901 cells. Fur-
ther studies are needed to deepen the insight because
the underlying mechanism is not known.
As shown in Fig. 6a, our western blot results showed
an increase in the expression of p53 (band at 53 kDa) of
etoposide and ECCNB-treated SGC-7901 cells compared
to the positive control. Wild-type p53 (a crucial G1
checkpoint) is well known to induce either cell cycle ar-
rest or apoptosis in cells that undergo DNA damage[35]. It demonstrated that ECCNBs may induce G2/M
cell cycle arrest and cell apoptosis possible through a
p53-related pathway when exposed on SGC-7901 cells
from this study.
The apoptosis pathway can be divided into caspase-
independent and caspase-dependent branches in mam-
malian cells. The activation of caspase family can lead to
the apoptosis of most of the proteolytic cleavages [36].
Caspases (a family of cysteine acid proteases) are cleaved
following proteolytic activation in early apoptosis [37].
The expression of caspase family is one of the com-
monly diagnostic tools for the detection of apoptosis
activity. Some of the caspase family proteins such as
Fig. 6 a Comparative effects of native etoposide, CCNBs, and ECCNBs on p53-related signaling pathway in SGC-7901 cells by immunoblotting
with specific antibodies mentioned in Materials and Methods. Effects of native etoposide, CCNBs, and ECCNBs on the expression of p53. b
Western blot illustrating expression of apoptotic markers in SGC-7901 cells. Cells in culture were exposed to 30 μg/mL of native etoposide,
CCNBs, and ECCNBs for indicated time periods. Effects of native etoposide, CCNBs and ECCNBs on the expression of caspase-7, caspase-8,
caspase-9, and Cyt C
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to mediate the apoptotic pathway. In this regard, west-
ern blot analysis was consistent to the apoptosis result
and confirmed our assumption that the expression of
caspase-9 and Cyt C was increased by ECCNBs in SGC-
7901 cell.
p53 mainly induced Bax and restrain the Bcl-2,
which can lead to the release of ATP and Cyt C in the
cytoplasm. ATP and Cyt C can combine with Apaf-1
to activate caspase-9 [38]. p53 also can promote re-
lated gene expression of oxidative stress. Expression
product can produce reactive oxygen species. The re-
active oxygen species can trigger the release of Cyt C,
and apoptosis initiation activated caspase protein
which leads to apoptosis [39]. As shown in Fig. 6b, the
western blot results showed an increase in the expres-
sion of Cyt C and caspase-9 of ECCNB-treated SGC-
7901 cells compared to that of etoposide. It suggeststhat ECCNBs can present an increased apoptotic effect
through mitochondrial pathway than free etoposide.Conclusions
In this study, we developed a facile method to prepare
CCNBs with citric acid as a crystal modifier to deliver
VP16 for cancer therapy. The experiments on CCNBs
as carriers for VP16 demonstrated the controlled re-
lease profile and enhanced cytotoxicity by increasing
cellular uptake and apoptosis against tumor cell. The
experiments of cell cytotoxicity and cell apoptosis
demonstrated that ECCNBs were more efficient than
native VP16 in delivery activity. ECCNBs can present
an increased apoptotic effect through mitochondrial
pathway than free VP16. It can be foreseen that
CCNBs is a promising drug carrier to store the anti-
cancer drug VP16 for cancer therapy.
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